 9. Exclusion 8 continued: c. Inducers and Inhibitors of Cytochrome P450 3A4 CYP3A4: Patients required to be on any CYP3A45 inhibitors or inducers will be excluded with the exception of Dexamethasone, but all efforts should be made to reduce the dose of dexamethasone. Patients must discontinue drug at least 7 days prior to starting dasatinib.d. Angiotensin-converting enzyme ACE inhibitors: Patients who are currently receiving ACE inhibitors are not eligible due to the development of angioneurotic edema-type reactions in some subjects who received concurrent treatment with temsirolimus ACE inhibitors. e. Anti-graft-versus-host disease GVHD or agents to prevent organ rejection post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial. 